ONCA Confirms Generics Limited to Section 8 Damages in the Face of an Innovator’s Legitimate Exercise of Rights under the PM(NOC) Regulations

Published date25 August 2022
AuthorAllyson Whyte Nowak, David Yi and Christopher A. Guerreiro
Subject MatterFood, Drug & Agriculture,Health Care
Law FirmNorton Rose Fulbright

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT